Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The aim of the present review is to analyze how thinking about the cardiovascular safety of nonsteroidal antiinflammatory drugs has evolved during the past two decades, and discuss to what extent the additional information from the Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen study may alter our current mechanistic understanding and/or clinical practice.

Original publication

DOI

10.1002/cpt.696

Type

Journal article

Journal

Clin Pharmacol Ther

Publication Date

08/2017

Volume

102

Pages

238 - 245

Keywords

Animals, Anti-Inflammatory Agents, Non-Steroidal, Cardiovascular Diseases, Cyclooxygenase 2 Inhibitors, Gastrointestinal Diseases, Humans, Prospective Studies, Randomized Controlled Trials as Topic, Risk Factors